FDA Approves IBANDRONATE SODIUM — Bionpharma Inc.

# FDA Approves Generic Ibandronate Sodium from Bionpharma Inc. Bionpharma Inc. has received FDA approval for its generic ibandronate sodium oral formulation, expanding treatment options in the osteoporosis market and likely intensifying price competition as additional generic alternatives become available. The approval of the ANDA application marks another entry into the bisphosphonate segment, which could pressure pricing for branded versions while improving patient access to this widely-prescribed bone health medication.